Roflumilast CAS 162401-32-3 Incida 99.0~101.0% API Featured Image

Roflumilast CAS 162401-32-3 Insidiari 99.0~ 101.0% API

Description:

Nomen chemicum: Roflumilast

CAS: 162401-32-3

Intenta: 99.0~ 101.0% (Ratio in Basis sicca)

Aspectus: Albus vel Fere Albus Crystallinus Pulvis

API PDE-4 Inhibitor COPD

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Roflumilast intermedia:
Roflumilast CAS 162401-32-3
4-Amino-3,5-Dichloropyridine CAS 22889-78-7

Chemical Properties:

Nomen chemicum	Roflumilast
Synonyma	3-(Cyclopropylmethoxy)-N-(3,5-Dichloropyridin-4-yl) -4-
CAS Number	162401-32-3
CATTUS Number	RF-PI2075
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C17H14Cl2F2N2O3
M. Pondus	403.21
Density	1.471±0.060 g/cm3
Sensibilitas	Calor Sensitiva
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba aut fere alba Crystallina pulveris
Solubilitas	In acetone solutum, in acetronitrili parce solubile, in ethanolo anhydroideum leviter solubile, in aqua fere solubile.
Liquescens punctum	157.0~162.0℃
Damnum in Siccatio	<0.50%
Residere in Ignition	≤0.10%
Metalla gravis	≤10ppm
Chloride	≤0.01%
Lepidium sativum A. UV	Maximi effusio necem debet esse in 213~251nm
Lepidium sativum B. IR	IR effusio spectri specimen correspondet relationis
Lepidium sativum C.	Hoc ostendit reactionem Fluoride
Substantiae cognatae
una immunditia	≤0.10%
Totalis immunditias	<0.50%
RELICTUM Solvents
Tert-Butanol	<0.10%
Tetrahydrofuran	<0.072%
Toluene	<0.089%
N,N-Dimethylformamide	<0.088%
Assay	99.0~ 101.0% (Ratio in Sicca Basis)
Test Standard	Enterprise Standard
Consuetudinem	API;COPD

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Roflumilast (CAS: 162401-32-3) phosphodiesterasus oralis selectivus 4 (PDE-4) inhibitor et compositi benzamidei.Societas Germanica Altana anno 1993 evoluta est et unicus PDE-4 inhibitor oris tractandi morbos tractus respiratorii approbatos pro sale.Roflumilast primum medicamentum sui generis est, ut gravem chronicam morbum pulmonis obstructorem (COPD) oppugnaat et est etiam primum medicamentum oris anti-inflammationis specie pro aegris COPD elaboratum.Proprietates singulares eius adiuvare possunt COPD moderari: cum usus in compositione cum bronchodilatoribus ad aegros COPD gravissimos tractandos adhibitus, Roflumilast commoditatem habet ulterioris reducendi symptomata et deminutio rate, ita primum medicamentum quod praebent aegros cum phaenotypo-spAecific COPD recurrente corrumpente. et gravis aeris impedimentum ad veterem tussim et pituitam superfluitatem pertinentium.Praeter curationem gravium COPD, Roflumilast etiam adhiberi potest ad praecavenda et tractanda pecora tractus respiratorii morbos, tussis bronchitis mucosa excessus, bronchitis asthmaticis, et sacculitis acutis bronchitis et aeris cum abnormis tractus respiratorii secretio.